Literature DB >> 22112007

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.

Massimo Breccia, Giuseppina Loglisci, Laura Cannella, Paola Finsinger, Marco Mancini, Alessandra Serrao, Michelina Santopietro, Adriano Salaroli, Giuliana Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22112007     DOI： 10.3109/10428194.2011.643408

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  11 in total

Review 1.  Predicting response to epigenetic therapy.

Authors:  Marianne B Treppendahl; Lasse S Kristensen; Kirsten Grønbæk
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

2.  Concise drug review: azacitidine and decitabine.

Authors:  Ellen J B Derissen; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2013-05-13

3.  Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.

Authors:  A M Zeidan; M A Sekeres; G Garcia-Manero; D P Steensma; K Zell; J Barnard; N A Ali; C Zimmerman; G Roboz; A DeZern; A Nazha; E Jabbour; H Kantarjian; S D Gore; J P Maciejewski; A List; R Komrokji
Journal:  Leukemia       Date:  2015-10-14       Impact factor: 11.528

Review 4.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

5.  Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Ju-Whei Lee; Thomas Prebet; Peter Greenberg; Zhuoxin Sun; Mark Juckett; Mitchell R Smith; Elisabeth Paietta; Janice Gabrilove; Harry P Erba; Martin S Tallman; Steven D Gore
Journal:  Br J Haematol       Date:  2014-04-09       Impact factor: 6.998

Review 6.  Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

Review 7.  Stopping higher-risk myelodysplastic syndrome in its tracks.

Authors:  Daniel A Pollyea; Jonathan A Gutman
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

8.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Authors:  Rafael Bejar; Allegra Lord; Kristen Stevenson; Michal Bar-Natan; Albert Pérez-Ladaga; Jacques Zaneveld; Hui Wang; Bennett Caughey; Petar Stojanov; Gad Getz; Guillermo Garcia-Manero; Hagop Kantarjian; Rui Chen; Richard M Stone; Donna Neuberg; David P Steensma; Benjamin L Ebert
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

9.  Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Roman M Shapiro; Alejandro Lazo-Langner
Journal:  BMC Hematol       Date:  2018-01-31

Review 10.  Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-05-28       Impact factor: 11.431
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.